Navigation Links
Common antibiotics and blood pressure medication may result in hospitalization
Date:1/17/2011

Mixing commonly used antibiotics with common blood pressure medications may cause hypotension (abnormally low blood pressure) and induce shock in older patients, requiring hospitalization, according to a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100702.pdf.

"Macrolide antibiotics (erythromycin, clarithromycin and azithromycin) are among the most widely prescribed antibiotics, with millions of prescriptions dispensed in Canada each year." writes Dr. David Juurlink, Scientist at the Sunnybrook Research Institute and the Institute for Clinical Evaluative Sciences with coauthors. "The drugs are generally well-tolerated, but they can cause several important drug interactions."

This study was conducted among Ontarians 66 years and older who were treated with a calcium-channel blocker (drugs often used to treat high blood pressure) between 1994 and 2009. The researchers then identified those who were hospitalized for low blood pressure and, in that group, whether or not a macrolide antibiotic had been prescribed shortly beforehand.

The researchers identified 7100 patients hospitalized for low blood pressure or shock while taking a calcium channel blocker. Treatment with erythromycin was found to increase the risk of low blood pressure almost 6-fold, while clarithromycin increased the risk almost 4-fold. In contrast, azithromycin did not increase the risk of hypotension.

"In older patients receiving calcium channel blockers, the two macrolide antibiotics erythromycin and clarithromycin are associated with a major increase in the risk of hospitalization for hypotension," conclude the authors. "However, the related drug azithromycin appears safe. When clinically appropriate, it should be used preferentially in patients receiving a calcium channel blocker."


'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Source:Eurekalert

Page: 1

Related biology news :

1. Study provides insight on a common heart rhythm disorder
2. Researchers identify Achilles heel of common childhood tumor
3. First comprehensive genomic study of common cold reveals new treatment targets
4. GUMC researchers hone in on new strategy to treat common infection
5. Hairspray is linked to common genital birth defect, says study
6. Common food additive found to increase risk and speed spread of lung cancer
7. Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases
8. Scientists uncover evolutionary keys to common birth disorders
9. Common soil mineral degrades the nearly indestructible prion
10. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
11. New vaccine developed for preventing uncommon cold virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2016)... WEST CHESTER, Ohio , Jan. 27, 2016 /PRNewswire/ ... services supplier based in West Chester, Ohio ... and their award winning service staff, based in ... Track,s technical capacity and ability to provide modifications, installations ... John Dovalina , CEO of PLUS, commented, "PLUS ...
(Date:1/21/2016)... --> ... report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, NLP, ... Voice Recognition and Others), Services, Application Areas, End ... published by MarketsandMarkets, the global Emotion Detection and ... Billion by 2020, at a CAGR of 31.9%, ...
(Date:1/15/2016)... Jan. 15, 2016 Recent publicized breaches in ... find new ways to ensure data security and user ... and Android that ties a user,s ... it into a hardware authorization token. Customer service agents ... fingerprint on their KodeKey enabled device to verify their ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... 4, 2016  CytoSorbents Corporation (NASDAQ: CTSO ... flagship CytoSorb® blood filter to treat deadly inflammation ... world, announced that CEO Dr. Phillip Chan ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference, ... Conference Presentation Details: Where: Convene ...
(Date:2/4/2016)... BEIJING , Feb. 4, 2016 Sinovac ... ), a leading provider of biopharmaceutical products in ... committee of its board of directors received on February ... 3, 2016, from a consortium comprised of PKU V-Ming ... Sinobioway Biomedicine Co., Ltd., CICC Qianhai Development ( ...
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
Breaking Biology Technology: